Cocrystal Pharma to Participate in Two Investor Conferences in November
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced participation in two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced participation in two investor conferences. On November 3, CFO James Martin will join a panel at the 2022 BioFlorida Annual Conference focusing on infectious diseases, held at Hyatt Regency Miami. Additionally, he will present a company overview at the Q4 Investor Summit on November 14 at Sheraton New York Time Square Hotel. A webcast of the Q4 Investor Summit will be available on the company’s IR Calendar page.
Details
News Market Reaction – COCP
The recorded move for COCP in the trading session of this news was +13.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investor conferences as follows:
- 2022 BioFlorida Annual Conference: James Martin, CFO and interim co-CEO, will participate in a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on Thursday, November 3 at 2:05 p.m. Eastern time. The conference is being held at Hyatt Regency Miami. More information about the conference is available here.
- Q4 Investor Summit: Mr. Martin will present a company overview on Monday, November 14 at 11:30 a.m. Eastern time. The conference is sponsored by the Investor Summit Group and is being held at the Sheraton New York Time Square Hotel. More information about the conference is available here.
A webcast of the Q4 Investor Summit presentation will be posted to the IR Calendar page of the company website.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.